Drug Profile
Tripotassium dicitrato bismuthate/tetracycline/metronidazole - Adare Pharmaceuticals
Alternative Names: Biskalcitrate potassium 140mg/metronidazole 125mg/tetracycline hydrochloride 125mg; Bismuth subcitrate/metronidazole/tetracycline - Adare Pharmaceuticals; Bismuth-based triple therapy - Adare Pharmaceuticals; Bismuth/metronidazole/tetracycline; Helicide; Helizide; PyleraLatest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Axcan Pharma
- Developer Adare Pharmaceuticals
- Class Cytoprotectives; Helicobacter pylori eradication therapies; Nitroimidazoles; Organometallic compounds; Tetracyclines
- Mechanism of Action DNA synthesis inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Helicobacter infections
Most Recent Events
- 30 Jun 2022 AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) enter into an asset purchase agreement for Tripotassium dicitrato bismuthate/tetracycline/metronidazole
- 01 Mar 2022 Tripotassium dicitrato bismuthate/tetracycline/metronidazole is not yet available for Helicobacter infections in Bulgaria, Greece, Hungary, Italy, Slovakia (NDR Batch 21)
- 05 Jul 2019 Tripotassium dicitrato bismuthate/tetracycline/metronidazole is not yet available for Helicobacter infections (Combination therapy) in Belgium, United Kingdom, Canada